Alcon (ALC) Stock News
$ALC · NYSE · 2 stories in 30 days$67.74
1D −0.15%
BORSA has published 2 stories on Alcon (ALC) in the past 30 days. BORSA’s news read on ALC is bullish at 67/100, +7 over 24 hours, based on 2 company events over the past 7 days. Alcon’s next earnings report is scheduled for Tuesday, Nov 10 after the close.
The wire on $ALC
newest first · updated · direct subject stories onlyAlcon acquires Neurotech and ENCELTO, the only FDA-approved MacTel treatment
Alcon paid $550 million for Neurotech Pharmaceuticals, gaining ENCELTO, the first FDA-approved treatment for MacTel Type 2. The deal expands Alcon's retina portfolio. Alcon expects modest accretion to sales growth in 2027.
bullish 65 · impact 60FDA clears Alcon's Brytly Redness Reliever Drops for 12-hour eye relief
The FDA has cleared Alcon's Brytly Redness Reliever Drops.
bullish 65 · impact 30